BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• Business

  Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

  Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab) today announced the company will issue a press release reporting its fourth quarter and full year 2023 financial results and providing a business update on March 7, 2024, at 7:00 am Eastern Time.

  February 14, 2024

   · 

  1 min read
• Drug Development

  Replicate Bioscience Announces Positive Initial Clinical Results for its Next Generation srRNA Technology

  Replicate Bioscience today shared positive results from the Phase 1 trial of RBI-4000, its srRNA-based rabies vaccine.

  February 14, 2024

   · 

  4 min read
• Pharm Country

  U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

  U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK -Positive Locally Advanced or Metastatic Solid Tumors.

  February 14, 2024

   · 

  17 min read
• Policy

  Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness

  Precision BioSciences, Inc. announced that the company has received pre-IND regulatory feedback from the U.S. Food and Drug Administration and ex-U.S. agencies.

  February 14, 2024

   · 

  10 min read
• Deals

  Satellos to Commence Trading on the Toronto Stock Exchange

  Satellos Bioscience Inc. announced today that its common shares will commence trading on the Toronto Stock Exchange (“TSX”) as of the opening of trading tomorrow under the Company’s current trading symbol, “MSCL”.

  February 14, 2024

   · 

  5 min read
• Business

  Microbix Reports Record Results for Q1 Fiscal 2024Record Revenues of $8.4 million and Record Net Income of $2.5 million

  Microbix Biosystems Inc. reports results for its first quarter of fiscal 2024 ended December 31, 2023 (“ Q1 ”).

  February 14, 2024

   · 

  6 min read
• Biotech Beach

  Evoke Pharma Announces Closing of $7.5 Million Public Offering

  Evoke Pharma, Inc. announced today that it has closed an underwritten public offering led by Nantahala Capital Management, with participation by other fundamental investors, for gross proceeds of up to $30 million.

  February 14, 2024

   · 

  6 min read
• Business

  IQVIA Reports Fourth-Quarter and Full-Year 2023 Results; Issues Full-Year 2024 Guidance

  IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended December 31, 2023.

  February 14, 2024

   · 

  21 min read
• Drug Development

  Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease

  Annovis Bio, Inc. today announced last patient last visit in the phase II/III study of its lead candidate buntanetap in patients with mild to moderate Alzheimer’s disease (AD).

  February 14, 2024

   · 

  3 min read
• Business

  Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024

  Ocugen, Inc. today announced that it will host an in-person Clinical Showcase on Wednesday, February 21, 2024.

  February 14, 2024

   · 

  3 min read